"This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pathway to effectively treat a range of dermatological diseases," remarked Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall.

Under the terms of the agreement, Almirall will spearhead the accelerated development of NN-8828, assuming responsibility for global development and future commercialization in specified indications. Novo Nordisk will receive an upfront payment, along with additional development and commercial milestone payments, and tiered royalties based on future global sales.

NN-8828 represents a pioneering advancement in dermatological therapy as a first-in-class, high-affinity monoclonal antibody targeting the cytokine IL-21. Developed by Novo Nordisk up to Phase II in non-dermatological indications, NN-8828 shows promise in blocking the activation of downstream signaling pathways associated with IL-21, thereby inhibiting the pathophysiological functions induced by this cytokine in various immune cells.

Dr. Ziegelbauer emphasized Almirall's dedication to improving the lives of patients suffering from skin diseases, expressing confidence in NN-8828's potential to address unmet medical needs in inflammatory and autoimmune skin disorders.

This collaboration marks a significant step forward in Almirall's commitment to advancing dermatological research and underscores its ongoing pursuit of cutting-edge therapies to meet the evolving needs of patients worldwide.